公开(公告)号：US20230295283A1

公开(公告)日：2023-09-21

申请号：US18066998

申请日：2022-12-15

申请人： BioArctic Neruoscience AB

发明人： Par Gellerfors ,  Lars Lannfelt ,  Linda Soderberg ,  Karin Tegerstedt

IPC分类号： C07K16/18 ,  C07K14/47

CPC分类号： C07K16/18 ,  C07K14/4711 ,  A61K38/00

摘要： A vaccine for delaying onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual comprises a therapeutically effective amount of a physiologically acceptable protofibril/oligomer comprising N-terminal truncated Aβ. An antibody for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual hinds one or more truncated Aβ protofibrils/oligomers, but exhibits no or substantially no cross-reactivity with full length Aβ monomers, and optionally said antibody shows cross-reactivity to N-terminal truncated Aβ monomers. Methods for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder employ the vaccine or antibody. Methods of detecting soluble N-terminal truncated amyloid-beta (Aβ) protofibrils/oligomers and N-terminal truncated Aβ monomers employ the antibody.